Differences in HCV Viral Decline between Low and Standard-Dose Pegylated-Interferon-Alpha-2a with Ribavirin in HIV/HCV Genotype 3 Patients

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Rivero Juárez, Antonio ^a,b   Lopez Cortes, Luis F ^c   Camacho, Angela ^a,b   Torres Cornejo, Almudena ^c   Pineda, Juan A ^d   Marquez Solero, Manuel ^e   Caruz, Antonio ^f   Ruiz Valderas, Rosa ^c   Torre Cisneros, Julian ^a,b   Gutierrez Valencia, Alicia ^c   Rivero, Antonio ^a,b  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b Maimonides Institute for Research in Biomedicine of Cordoba   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^f UNIVERSITY OF JAÉN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER FIBROSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRAL DECLINE; VIRAL PHENOMENA AND FUNCTIONS; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; COINFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIV; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

HEPATITIS C VIRUS;

EID: 84869026751     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048959     Document Type: Article

References (26)

1. Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, et al. (2004) Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV coinfected Persons. N Engl J. Med. 351: 451-459.
2. Torriani F, Rodriguez-Torres M, Rockstroh J, Lissen E, Gonzalez-García J, et al. (2004) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 351: 438-450.
3. Rivero-Juarez A, Camacho A, Perez-Camacho I, Neukam K, Caruz A, et al. (2012) Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4. J Antimicrob Chemother. 67: 202-5.
4. Bochoud PY, Cai T, Overbeck K, Bochud M, Dufour JF, et al. (2009) Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol. 51: 655-66.
5. Probst A, Dang T, Bochud M, Egger M, Negro F, et al. (2011) Role of hepatitis C virus genotype 3 in liver fibrosis progression: a systematic review and meta-analysis. J Viral Hepat. 18: 745-59.
6. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, et al. (2011) HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat. 18: e516-22 doi: 10.1111/j.1365-2893.2011.01441.x.
7. Ghany MG, Strader DB, Thomas DL, Seeff LB, (2009) Diagnosis, Management and Treatment of Hepatitis C: An update. AASLD Practice Guidelines. Hepatology. 49: 1335-1374.
8. Sulkowski MS, (2008) Viral hepatitis and HIV coinfection. J Hepatol. 48: 353-367.
9. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, et al. (2009) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 361: 580-93.
10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347: 975-82.
11. Weiland O, Hollander A, Mattson L, Glaumann H, Lindahl K, et al. (2008) Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat. 15: 641-5.
12. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P, (2010) Viral hepatitis and HIV co-infection. Antiviral Res. 85: 303-315.
13. Operskalski E, Kovacs A, (2011) HIV/HCV Co-infection: Pathogenesis, clinical complications, treatment, and new therapeutic technologies. Curr HIV/AIDS Rep. 8: 12-22.
14. Suzuki H, Kakizaki S, Horiguchi N, Ichikawa T, Sato K, et al. (2010) Clinical characteristics of null responders to Peg-IFNα2b/ribavirin therapy for chronic hepatitis C. WJH. 2: 401-405.
15. Boulestin A, Kamar N, Sandres-Saune K, Legrand-Abravanel F, Alric L, et al. (2006) Twenty-four kinetics of hepatitis C virus and antiviral effect of alpha-interferon. J Medical Virology. 78: 365-371.
16. Nomura H, Mitagi Y, Tanimoto H, Ishibashi H, (2009) Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C. J Viral Hepat. 16: 346-351.
17. Milan M, Boninsegna S, Scribano S, Lobello S, Fagiuoli S, et al. (2012) Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients? Infection. 40: 173-9.
18. Parruti G, Polilli E, Sozio F, Cento V, Pieri A, et al. (2010) Rapid Prediction of sustained virological response in patients chronically infected with HCV by evaluation of RNA decay 48 h after the start of treatment with pegylated interferon and ribavirin. Antiviral Research. 88: 124-127.
19. Durante-Mangoni E, Zampino R, Portella G, Adinolfi LE, Utili R, et al. (2009) Correlates and prognostic value of the first-phase hepatitis C virus RNA kinetics during treatment. Clin Infect Dis. 49: 498-506.
20. Lopez-Cortes LF, Ruiz-Valderas R, Jimenez-Jimenez L, González-Escribano MF, Torres-Cornejo A, et al; on behalf of the Grupo para el estudio de las hepatitis víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI) (2012) Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α-2a for genotype 3 chronic hepatitis C in HIV-coinfected patients. Plos ONE. 7: e28115 Doi:10.1371/journal.pone.0028115.
21. Macias J, Recio E, Vispo E, Rivero A, López-Cortés LF, et al. (2008) Application of transient elastometry to differentiate mild from moderate to severe fibrosis in HIV/HCV co-infected patients. J Hepatol. 49: 916-22.
22. Pockros PJ, Carithers R, Desmond P, Dhumeaux D, (2004) PEGASYS International Study Group, et al (2004) Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter randomized controlled trial. Am J Gastroenterol. 99: 971-81.
23. Jacobson IM, Brown RS, Freilich B, Afdhal N, (2007) WIN-R Study Group, et al (2007) Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 46: 971-81.
24. Ferenci P, Brunner H, Laferl H, Scherzer TM, (2008) Austrian Hepatitis Study Group, et al (2008) A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotype 2 and 3. Hepatology. 47: 1816-23.
25. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, et al. (2010) Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis. 51: 788-95.
26. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 461: 399-401.